Taken together, these findings not only pinpoint a novel metabolic reprogramming process driving lung cancer metastasis but also provided compelling evidence that targeting urea cycle, especially through CPS1 inhibition, could be an effective therapeutic strategy. Here, CPS1 is linked to lung carcinoma.